These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14520605)

  • 1. Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus.
    Tentolouris N; Kolia M; Tselepis AD; Perea D; Kitsou E; Kyriaki D; Tambaki AP; Karabina SP; Sala C; Fragoulopoulos E; Katsilambros N
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):370-3. PubMed ID: 14520605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels.
    Skrapari I; Perrea D; Ioannidis I; Karabina SA; Elisaf M; Tselepis AD; Karagiannacos P; Katsilambros N
    Diabet Med; 2001 Oct; 18(10):781-5. PubMed ID: 11678967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
    Moses R; Slobodniuk R; Boyages S; Colagiuri S; Kidson W; Carter J; Donnelly T; Moffitt P; Hopkins H
    Diabetes Care; 1999 Jan; 22(1):119-24. PubMed ID: 10333912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
    Rizzo MR; Barbieri M; Grella R; Passariello N; Paolisso G
    Diabetes Metab; 2005 Jun; 31(3 Pt 1):255-60. PubMed ID: 16142016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postprandial lipid metabolism and beta-cell function in non-insulin-dependent (type 2) diabetes mellitus after a mixed meal with a high fat content.
    Cooper MB; Tan KC; Hales CN; Betteridge DJ
    Diabet Med; 1996 Sep; 13(9):816-27. PubMed ID: 8891457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.
    Rizzo MR; Barbieri M; Grella R; Passariello N; Barone M; Paolisso G
    Diabetes Metab; 2004 Feb; 30(1):81-9. PubMed ID: 15029102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide versus glyburide: a one-year comparison trial.
    Marbury T; Huang WC; Strange P; Lebovitz H
    Diabetes Res Clin Pract; 1999 Mar; 43(3):155-66. PubMed ID: 10369424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
    Van Gaal LF; Van Acker KL; De Leeuw IH
    Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
    Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
    Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of casein on postprandial lipemia and incretin responses in type 2 diabetic subjects.
    Brader L; Holm L; Mortensen L; Thomsen C; Astrup A; Holst JJ; de Vrese M; Schrezenmeir J; Hermansen K
    Nutr Metab Cardiovasc Dis; 2010 Feb; 20(2):101-9. PubMed ID: 19473824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
    Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
    Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus.
    Rudovich N; Möhlig M; Otto B; Pivovarova O; Spranger J; Weickert MO; Pfeiffer AF
    Diabetes Technol Ther; 2010 Jan; 12(1):57-64. PubMed ID: 20082586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
    Mori Y; Itoh Y; Obata T; Tajima N
    Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
    Esposito K; Giugliano D; Nappo F; Marfella R;
    Circulation; 2004 Jul; 110(2):214-9. PubMed ID: 15197140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide as monotherapy in Type 2 diabetes.
    Gomis R
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S133-5. PubMed ID: 10522838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
    Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
    Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.